Predictors of cerebrospinal fluid GeneXpert MTB/RIF positivity in patients with tuberculous meningitis: A prospective cohort study

Abstract

Objective: To identify the clinical, laboratory, and radiological markers that could predict a positive GeneXpert result in patients suspected of tuberculous meningitis.

Methods: In this prospective, observational study, patients with tuberculous meningitis were systematically evaluated. Various clinical, laboratory [including cerebrospinal fluid (CSF) microscopy, culture, and GeneXpert], and neuroimaging factors were examined. All participants were administered anti-tuberculous treatment and corticosteroids. A six-month follow-up was done to evaluate the outcome.

Results: Of the 116 patients studied, 54 (46.6%) tested positive for GeneXpert, while 62 (53.4%) were negative. Third cranial nerve involvement (OR 3.71, 95% CI 1.052-13.09, P=0.04) and the presence of basal exudates on neuroimaging (OR 5.22, 95% CI 2.03-13.42, P=0.001) emerged as independent predictive factors for a positive GeneXpert result. A positive CSF GeneXpert result (P=0.002) and drug resistance (P=0.004) were significantly linked to adverse outcomes. Additionally, a high score on the Medical Research Council stage III (OR 5.64, 95% CI 1.18-26.87, P=0.03) and elevated CSF cell counts (OR 1.002, 95% CI 1.00-1.001, P=0.03) were identified as independent predictors of poor prognosis.

Conclusions: Third cranial nerve involvement and the presence of basal exudates were significant indicators of a positive GeneXpert result. MRC stage III disability and elevated CSF cell counts predicted poor outcomes.

Keywords

Tuberculous meningitis / Cerebrospinal fluid / Ziehl-Neelsen staining / GeneXpert

References

[1] Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. Tuberculous Meningitis International Research Consortium. The current global situation for tuberculous meningitis: Epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res 2019; 4: 167. doi: 10.12688/ wellcomeopenres.15535.1.

[2] Mai NT, Thwaites GE. Recent advances in the diagnosis and management of tuberculous meningitis. Curr Opin Infect Dis 2017; 30(1): 123-128. doi: 10.1097/QC0.0000000000000331.

[3] Stadelman AM, Ssebambulidde K, Buller A, Tugume L, Yuquimpo K, Bakker CJ, et al. Cerebrospinal fluid AFB smear in adults with tuberculous meningitis: A systematic review and diagnostic test accuracy meta-analysis. Tuberculosis (Edinb) 2022; 135: 102230.

[4] Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al. Tuberculous Meningitis International Research Consortium. Tuberculous meningitis. Nat Rev Neurol 2017; 13(10): 581-598.

[5] Garg RK. Microbiological diagnosis of tuberculous meningitis: Phenotype to genotype. Indian J Med Res 2019; 150(5): 448-457.

[6] National Health Mission. Central TB Division. India TB report 2019: Revised National Tuberculosis Control Programme. New Delhi: Ministry of Health & Family Welfare, Government of India; 2019. [Online]. Available from: https://tbcindia.gov.in/WriteReadData/India%20TB%20 Report%202019.pdf. [6 October 2023].

[7] Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. Tuberculous meningitis: A uniform case definition for use in clinical research. Lancet Infect Dis 2010; 10: 803-812.

[8] Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351(17): 1741-1751.

[9] World Health Organization. Guidelines for treatment of tuberculosis fourth edition 2010. [Online]. Available from: http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1. [6 October 2023].

[10] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. [Online]. Available from: https://iris.who.int/bitstream/handle/10665/365308/9789240063129-eng.pdf?sequence=1. [28 July 2024].

[11] Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel index for stroke rehabilitation. J Clinical Epidemiol 1989; 42: 703-709.

[12] Garg RK. Tuberculous meningitis. Acta Neurol Scand 2010; 122(2): 75-90.

[13] Wen A, Cao WF, Liu SM, Zhou YL, Xiang ZB, Hu F, et al. Incidence and risk factors of cranial nerve palsy in patients with tuberculous meningitis: A retrospective evaluation. Infect Drug Resist 2023; 16: 829-841.

[14] Martyn EM, Bangdiwala AS, Kagimu E, Rutakingirwa MK, Kasibante J, Okirwoth M, et al. Cerebrospinal fluid bacillary load by Xpert MTB/ RIF ultra polymerase chain reaction cycle threshold value predicts 2-week mortality in human immunodeficiency virus-associated tuberculous meningitis. Clin Infect Dis 2021; 73(9): e3505-e3510.

[15] Nhu NT, Heemskerk D, Thu do DA, Chau TT, Mai NT, Nghia HD, et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. J Clin Microbiol 2014; 52(1): 226-233. doi: 10.1128/JCM.01834-13.

[16] Krishnakumariamma K, Ellappan K, Muthuraj M, Tamilarasu K, Kumar SV, Joseph NM. Molecular diagnosis, genetic diversity and drug sensitivity patterns of Mycobacterium tuberculosis strains isolated from tuberculous meningitis patients at a tertiary care hospital in South India. PLoS One 2020; 15(10): e0240257. doi: 10.1371/journal. pone.0240257.

[17] Harahap MIR, Soetikno RD, Anwary F. Relationship between neutrophil count in cerebrospinal fluid and cerebral infarct appearance in head MRI on tuberculous meningitis patients. Eur J Radiol Open 2022; 10: 100469.

[18] Huynh J, Donovan J, Phu NH, Nghia HDT, Thuong NTT, Thwaites GE. Tuberculous meningitis: Progress and remaining questions. Lancet Neurol 2022; 21(5): 450-464. doi: 10.1016/S1474-4422(21)00435-X.